Can Cancerous Lung Nodules Be Removed?

Cancerous lung nodules can be removed, and surgical removal remains the most effective treatment for early-stage lung cancer. The specific approach depends on the nodule’s size, location, and stage, as well as the patient’s overall health and lung function. For people who cannot tolerate surgery, alternatives like stereotactic radiation and thermal ablation can destroy nodules without an incision. The landscape of options has expanded considerably in recent years, so the question is less about whether removal is possible and more about which method fits a given situation.

How Doctors Decide Whether a Nodule Needs to Come Out

Not every lung nodule is cancerous, and not every cancerous nodule requires immediate surgery. The decision-making process starts with estimating how likely a nodule is to be malignant. Guidelines from the American College of Chest Physicians emphasize assessing that probability through imaging characteristics, patient history, and sometimes biopsy before choosing between surveillance, nonsurgical biopsy, or surgical resection.¹ A small, ground-glass nodule that hasn’t changed over several CT scans might be watched safely. A larger solid nodule that’s growing, especially in someone with a smoking history, is more likely to prompt a recommendation for removal.

Emerging blood-based tests are adding a new layer to this evaluation. Researchers have studied circulating tumor DNA, microRNAs, circulating tumor cells, and tumor-associated autoantibodies as ways to help distinguish malignant nodules from benign ones without invasive biopsy.² These liquid biopsies are not yet standard practice for routine nodule evaluation, but they represent a direction the field is moving toward, particularly for nodules that fall into the uncertain middle ground between clearly benign and clearly suspicious.

Assessing Whether You Can Handle the Surgery

Even when a nodule is confirmed cancerous, surgery only makes sense if your body can tolerate the loss of lung tissue. Before any lung cancer operation, doctors test respiratory function. The key measurements are how much air you can forcefully exhale in one second and how efficiently your lungs transfer oxygen to your blood. If both of those values are above about 80% of what’s predicted for your age and size, a major resection is generally considered safe. When either falls below that threshold, additional exercise testing helps determine just how much risk the operation carries.³

People with chronic obstructive pulmonary disease face a particular dilemma. Research supports that patients with mild-to-moderate COPD should not be denied surgery based on their lung disease alone.⁴ Severe COPD is a different story. One study found no deaths within the first 90 days after surgery among patients with severe COPD, but their five-year survival was roughly 42% compared with about 61% for those with less severe disease, reflecting an approximately 70% increased risk of dying over the long term.⁵ So surgery can still be performed safely in the short term for these patients, but the decision requires careful individual weighing of risks and benefits. In select cases, surgeons have even combined lung cancer resection with lung volume reduction surgery for severe COPD patients, improving both cancer control and breathing function simultaneously.⁶

Surgical Approaches for Removing Cancerous Nodules

When surgery is the plan, the three main options involve removing different amounts of lung tissue. A lobectomy takes out the entire lobe of the lung that contains the nodule and has been the gold standard for decades. A segmentectomy removes just the segment of the lobe where the tumor sits. A wedge resection cuts out the tumor along with a small margin of surrounding tissue, without following the lung’s natural anatomical boundaries.

For early-stage tumors under about 2 centimeters, segmentectomy has gained strong support as an alternative to lobectomy. A systematic review and meta-analysis found that survival after segmentectomy was not inferior to that after lobectomy for stage I non-small cell lung cancer.⁷ Segmentectomy is particularly valuable for patients whose lung function might not tolerate losing an entire lobe.⁸

That said, the comparison between smaller resections and lobectomy isn’t entirely settled. A meta-analysis comparing sublobar resection (which includes both segmentectomy and wedge resection) with lobectomy for solid-dominant stage IA cancers found no significant difference in overall survival, but lobectomy was associated with better recurrence-free survival.⁹ In practical terms, this means that while patients may live just as long after a smaller operation, their cancer may be somewhat more likely to come back locally. The tradeoff between preserving lung tissue and reducing recurrence risk is something surgeons weigh carefully for each patient.

Minimally Invasive and Robotic Surgery

Most lung cancer surgery today is performed through small incisions rather than a large chest opening. The two dominant approaches are video-assisted thoracoscopic surgery, commonly known as VATS, and robotic-assisted surgery. Both allow surgeons to operate through a few small ports using a camera and specialized instruments, resulting in less pain, shorter hospital stays, and faster recovery compared with open surgery.

Comparisons between VATS and robotic approaches show the two are broadly similar in outcomes. Robotic lobectomies tend to take about 15 to 20 minutes longer in the operating room.¹⁰ One study found that robotic surgery resulted in less blood loss during the operation, though this didn’t translate into differences in hospital stay, complications, or 30-day readmission rates.¹¹ For segmentectomy specifically, a multi-institutional comparison found essentially identical outcomes between robotic and VATS approaches in operative time, complications, and length of stay, though robotic surgery was more expensive due to the cost of the robotic system and its disposable components.¹² The robotic approach did sample more lymph nodes, which could theoretically improve staging accuracy, though whether this improves long-term outcomes remains an open question.

Finding Small Nodules During Surgery

One practical challenge in removing small lung nodules is simply finding them during the operation. A nodule that shows up clearly on a CT scan can be invisible and impossible to feel when a surgeon is working through tiny incisions with a camera. This has driven the development of localization techniques that mark the nodule before or during surgery.

Methods include placing a wire through the skin into the nodule under CT guidance, injecting dye near the lesion, and using intraoperative ultrasound.¹³ A more recent development uses electromagnetic navigation bronchoscopy to guide a catheter through the airways to the nodule, where a fluorescent dye is injected. This dye then glows under near-infrared light during surgery, showing the surgeon exactly where to cut. A prospective study of 80 patients with deep lung nodules reported a 97.5% success rate for this technique, with no significant complications.¹⁴ These advances have made it feasible to perform tissue-sparing resections on nodules that would have been difficult to locate with older techniques.

Why Surgical Margins Matter

When a surgeon removes a cancerous nodule, the goal is to cut far enough from the tumor that no cancer cells are left behind. The distance between the edge of the tumor and the edge of the removed tissue is called the surgical margin, and it has a direct relationship with recurrence risk. A review of the evidence found that a margin of roughly 9 to 15 millimeters is generally sufficient, and greater margin distances are associated with better survival and lower rates of local recurrence.¹⁵

The type of nodule changes the equation. For solid tumors, a narrow margin of 5 millimeters or less dramatically increases the risk of cancer coming back; one study reported five-year recurrence-free survival of only about 24% with narrow margins compared with roughly 80% with wider margins.¹⁶ Ground-glass nodules, by contrast, showed no recurrence regardless of margin width in the same study. Similarly, tumors with a “lepidic” growth pattern, where cancer cells spread along existing lung structures rather than forming a dense mass, showed 100% five-year recurrence-free survival regardless of margin width.¹⁷ This means that for less aggressive-looking nodules, surgeons can often get away with removing less tissue, preserving more lung function without compromising cancer control.

What Happens When You Have Multiple Nodules

Finding more than one suspicious nodule complicates the picture but does not necessarily rule out surgery. When multiple nodules sit in the same lobe, wedge resection or segmentectomy can often address them. If the nodules are spread throughout one lobe, a lobectomy may be the simplest approach. When nodules appear in different lobes on the same side, evidence supports removing them all in a single operation when possible, because nodules removed at the time of surgery are substantially more likely to be malignant than those left for follow-up.¹⁸

Bilateral nodules, meaning nodules in both lungs, present the greatest challenge. Traditional practice favored operating on one side at a time, but recent data suggest that patients in good overall condition can undergo simultaneous bilateral surgery without increased complications. When bilateral surgery isn’t advisable, the larger or more worrisome nodule is addressed first, and surgeons try to avoid lobectomy to preserve as much lung tissue as possible for any future procedures.¹⁸

Alternatives When Surgery Isn’t Possible

For patients whose lung function, age, or other medical conditions make surgery too risky, several non-surgical options can still eliminate cancerous nodules. Stereotactic body radiation therapy, or SBRT, delivers highly focused, high-dose radiation to the tumor over a few sessions. In elderly patients aged 80 and older with early-stage lung cancer, SBRT achieved five-year local control rates of roughly 85 to 87%.¹⁹²⁰ Those are impressive numbers for a non-invasive treatment, though overall survival is lower than after surgery, partly because the patients selected for SBRT tend to be sicker to begin with.

Thermal ablation is another option. A needle is inserted through the chest wall into the tumor, and energy is applied to destroy it with heat or cold. Radiofrequency ablation, the most studied technique, achieves local control rates in the range of 80 to 90% for tumors under 3 centimeters.²¹ Microwave ablation tends to perform better for larger tumors, while cryoablation, which freezes the tissue, causes the least collateral damage and is preferred for tumors in critical locations near major airways or blood vessels.²² For small tumors, cryoablation and microwave ablation produce similar survival outcomes, but microwave clearly outperforms cryoablation for tumors larger than 3 centimeters.²³

Cost is worth considering. A comparison between microwave ablation and VATS surgery for ground-glass nodule lung cancer found that ablation cost less than half as much and required a significantly shorter hospital stay, with comparable three-year survival rates.²⁴ This makes ablation an attractive option not just for patients who cannot undergo surgery but potentially for those with very small, low-risk nodules who want a less invasive and less expensive treatment.

Bronchoscopic Ablation From the Inside

One of the newest frontiers is destroying lung nodules through the airways rather than through the chest wall. Robotic bronchoscopy platforms can navigate a thin catheter through the branching airways directly to a nodule, then deliver energy to ablate it. Early case reports describe using a robotic bronchoscope to navigate to a nodule and destroy it with a laser.²⁵ A small retrospective series of nine patients who underwent robotic bronchoscopy-guided microwave ablation reported 100% technical success with one case of post-procedure pneumonia and no other major complications.²⁶ This approach is still investigational and limited to a handful of centers, but it could eventually offer a way to treat deep lung nodules without any external incision at all.

Complications and Recovery After Lung Surgery

Air leaks are among the most common complications following lung resection. They happen when air escapes from the cut surface of the remaining lung into the space around it.²⁷ Most air leaks seal on their own within a few days. Prolonged air leaks, typically defined as lasting more than five days, occur in roughly one in ten patients after VATS lung resection and substantially increase hospital stay, from an average of about 9 days to nearly 20 days. Patients with prolonged air leaks also face a threefold higher risk of postoperative infection.²⁸ When an air leak persists beyond about a week, a chemical procedure to seal the space around the lung is effective; one study found that all persistent air leaks resolved within 24 hours of this treatment.²⁹

Lung function inevitably drops after removing lung tissue, but the decline is usually less dramatic than people fear, especially with minimally invasive techniques. Advances in surgical approach, from open thoracotomy to VATS and robotic surgery, have progressively reduced how much lung function is lost and how quickly it recovers.³⁰ Most patients notice shortness of breath with heavy exertion in the early weeks but gradually return to near-normal daily activity.

Treatment Before and After Surgery

Surgery alone is often the complete treatment for very early-stage lung cancer. But for stage II and stage IIIA disease, chemotherapy after surgery has become standard. Cisplatin-based regimens given after complete resection improve survival in these more advanced cases.³¹ More recently, immunotherapy has entered the picture. The drug pembrolizumab, given after surgery and chemotherapy in patients with stage IB through IIIA disease, extended the median time before cancer recurred from about 35 months with placebo to about 59 months.³²

Treatment before surgery, called neoadjuvant therapy, is also gaining traction. Giving immunotherapy combined with chemotherapy before the operation can shrink tumors and even eliminate cancer cells entirely in some patients. The CheckMate 816 trial found that adding nivolumab to chemotherapy before surgery achieved a complete disappearance of cancer in the surgical specimen in 24% of patients, compared with only about 2% with chemotherapy alone.³³ Neoadjuvant immunotherapy has been well tolerated and does not appear to delay surgery or increase surgical complications.³⁴ For patients with borderline-resectable or locally advanced disease, pre-surgical treatment can sometimes convert a tumor that initially looked inoperable into one that can be safely removed.³⁵

Surveillance After Removal

Getting a cancerous nodule out is not the end of the story. Lung cancer can recur in the remaining lung or at distant sites, and new primary lung cancers can develop, especially in people with a smoking history. The American Society of Clinical Oncology recommends CT scans every six months for two years after curative-intent treatment, then annually to watch for new primary lung cancers. PET/CT scans should not be used for routine surveillance.³⁶ Most recurrences and second primary cancers are caught by CT scans in patients who have no symptoms, underscoring why sticking with the follow-up schedule matters.³⁷

The Psychological Weight of a Lung Nodule Diagnosis

What gets less attention in clinical discussions is how distressing it is to learn you have a lung nodule. A scoping review found that anxiety affects anywhere from about 10% to 42% of patients with pulmonary nodules, and depression affects roughly 15% to 27%. Distress was even more common, reported in up to 57% of patients. This psychological burden is not just unpleasant; it can influence clinical decisions, sometimes pushing patients toward more aggressive treatment than the nodule warrants, and other times causing people to skip follow-up appointments entirely.³⁸

Factors that increase anxiety include having solid-appearing nodules, multiple nodules, a family history of lung cancer, and difficulty performing daily activities.³⁹ Some patients hope that choosing surgery will relieve their anxiety, but the evidence on this is sobering. A prospective study comparing patients who chose surgery with those who chose surveillance found that both groups experienced similar reductions in anxiety over the following year. Surgery did not provide additional psychological relief beyond what time and reassurance accomplished on their own.⁴⁰ That finding is worth knowing, because it means anxiety alone is not a good reason to push for an operation on a nodule that doctors believe is safe to watch.